<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>SMAD4 mutations and recent genome-wide association studies (GWAS) show the importance of bone morphogenetic protein (BMP) and transforming growth factor-β (TGF-β) signalling in the development of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Loss of SMAD4 has been implicated as a predictive marker in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>As activation of the BMP and TGF-β pathways leads to phosphorylation of SMAD1,5,8 and SMAD2,3, respectively, and both need SMAD4 for translocation to the nucleus, we aimed to investigate whether nuclear staining of pSMAD1,5,8 and pSMAD2, 3 can be used as predictive markers in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A tissue microarray (<z:chebi fb="39" ids="18139,53050">TMA</z:chebi>) was constructed using tissue from 209 patients diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="39" ids="18139,53050">TMA</z:chebi> was stained and scored for the nuclear presence of SMAD4, pSMAD2,3 and pSMAD1,5,8 </plain></SENT>
<SENT sid="5" pm="."><plain>Loss of SMAD4, pSMAD2,3 and pSMAD1,5,8 was observed in 40, 38 and 73% of the cases, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The incidence of SMAD4 loss was significantly higher in the advanced stages </plain></SENT>
<SENT sid="7" pm="."><plain>There was a correlation between loss of SMAD4 and loss of pSMAD1,5,8, but not between loss of SMAD4 and loss of pSMAD2,3 </plain></SENT>
<SENT sid="8" pm="."><plain>Loss of SMAD4 correlated with a poorer survival </plain></SENT>
<SENT sid="9" pm="."><plain>Loss of one of the pSMADs did not correlate with a poorer outcome </plain></SENT>
<SENT sid="10" pm="."><plain>Combining different SMAD stainings did not improve the prediction </plain></SENT>
<SENT sid="11" pm="."><plain>SMAD4 expression is a prognostic marker in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Nuclear expressions of pSMAD1,5,8 and pSMAD2,3 are not useful prognostic markers in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>